Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563576 · ClinicalTrials.gov registry record · NA
Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation
A NA study of Metrorrhagia, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT00563576: Completed NA study of Metrorrhagia, sponsored by Columbia University.
NCT00563576 is a NA study of Metrorrhagia that has completed, run by Columbia University. The registered enrollment target is 71 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00563576, a NA study of Metrorrhagia, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
Many women choose Depo-Provera for birth control because it is easy to use and very effective. However, a significant number of Depo-Provera users experience irregular bleeding during the first 90 days. Many users discontinue after their first injection due to irregular bleeding. This study will evaluate the effect of using an estrogen vaginal ring during the first 90 days of Depo-Provera use to see if it is acceptable to women and whether it decreases irregular bleeding during the first 90 days of use and increases continuation to a second injection.
Primary Outcome
Bleeding and spotting were defined using World Health Organization criteria and measured through daily diaries given to participants and collected at the 3 and 6 month followup. In addition, a study staff member called participants weekly to collect the daily bleeding and spotting calendar for that week to optimize the accuracy of this information.
Conditions Studied
Interventions
- DRUG Femring®
- DRUG DepoProvera ®
Study Locations (1)
New York
- Title X Family Planning Clinic - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-02 |
| Phase | NA |
What the finished NCT00563576 record still lists
NCT00563576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Metrorrhagia appearing as the primary indexed condition, and to 2 interventions - of which Femring® is the first listed.
NCT00563576 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00563576 about?
NCT00563576 is a clinical study titled "Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation". Many women choose Depo-Provera for birth control because it is easy to use and very effective. However, a significant number of Depo-Provera users experience irregular bleeding during the first 90 days. Many users discontinue after their first injection due to irregular bleeding. This study will eva...
What is the current status of trial NCT00563576?
This trial is currently completed. It is a NA study. The enrollment target is 71 participants. The study started on 2007-09. Estimated completion is 2009-02.
What conditions does trial NCT00563576 study?
This clinical trial studies the following conditions: Metrorrhagia.
What interventions are being tested in trial NCT00563576?
The interventions under investigation include: Femring® (DRUG), DepoProvera ® (DRUG).
Who is sponsoring clinical trial NCT00563576?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00563576 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metrorrhagia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00563576's enrollment target sits among peer trials
71 1102nd of 2000 higher than 898 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia